Neuroinflammation in Huntington's disease

被引:133
|
作者
Moeller, Thomas [1 ]
机构
[1] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA
关键词
Neuroinflammation; Microglia; Huntington's disease; Non-cell autonomous; Neurodegenerative disease; Glia; CELL-CELL INTERACTIONS; MUTANT HUNTINGTIN; MOUSE MODEL; KYNURENINE PATHWAY; MICROGLIAL ACTIVATION; GLIAL-CELLS; NEURODEGENERATIVE DISEASES; PARKINSONS-DISEASE; BRAIN INFLAMMATION; GENE-EXPRESSION;
D O I
10.1007/s00702-010-0430-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Huntington's disease (HD) is a monogenic neurodegenerative disease characterized by abnormal motor movements, personality changes and early death. In contrast to other neurodegenerative diseases, very little is known about the role of neuroinflammation in HD. While the current data clearly demonstrate the existence of inflammatory processes in HD pathophysiology, the question of whether neuroinflammation is purely reactive or might actively participate in disease pathogenesis is currently a matter of ongoing research and debate. This review will try to shed some light on the current state of research in this area and provide an outlook on potential future developments.
引用
收藏
页码:1001 / 1008
页数:8
相关论文
共 50 条
  • [41] Neuroinflammation in Parkinson’s Disease
    Jae-Kyung Lee
    Thi Tran
    Malú G. Tansey
    Journal of Neuroimmune Pharmacology, 2009, 4 : 419 - 429
  • [42] Huntington's Disease and Mitochondria
    Farshbaf, Mohammad Jodeiri
    Ghaedi, Kamran
    NEUROTOXICITY RESEARCH, 2017, 32 (03) : 518 - 529
  • [43] In vivo PET imaging of neuroinflammation in Alzheimer's disease
    Lagarde, Julien
    Sarazin, Marie
    Bottlaender, Michel
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (05) : 847 - 867
  • [44] Voltage-Gated Proton Channel Hv1 Regulates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson's Disease Models
    Neal, Matthew L.
    Beier, Eric E.
    Hossain, Muhammad M.
    Boyle, Alexa
    Zheng, Jiaying
    Kim, Chunki
    Mhatre-Winters, Isha
    Wu, Long-Jun
    Richardson, Jason R.
    ANTIOXIDANTS, 2023, 12 (03)
  • [45] Inflammation and Huntington's disease - a neglected therapeutic target?
    Field, Sophie E.
    Curle, Annabel J.
    Barker, Roger A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (05) : 451 - 467
  • [46] Neuroprotective Effects of Psychotropic Drugs in Huntington's Disease
    Lauterbach, Edward C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (11) : 22558 - 22603
  • [47] Protein Misfolding and ER Stress in Huntington's Disease
    Shacham, Talya
    Sharma, Neeraj
    Lederkremer, Gerardo Z.
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2019, 6
  • [48] Challenges of Huntington's disease and quest for therapeutic biomarkers
    Kotrcova, Eva
    Jarkovska, Karla
    Valekova, Ivona
    Zizkova, Martina
    Motlik, Jan
    Gadher, Suresh Jivan
    Kovarova, Hana
    PROTEOMICS CLINICAL APPLICATIONS, 2015, 9 (1-2) : 147 - 158
  • [49] Treatment of Huntington's Disease
    Frank, Samuel
    NEUROTHERAPEUTICS, 2014, 11 (01) : 153 - 160
  • [50] Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson's Disease
    Wallin, Johan
    Svenningsson, Per
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)